Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02808975 · ClinicalTrials.gov registry record · Phase 4
Safety and Efficacy of Adalimumab (Humira) for Hidradenitis Suppurativa (HS) Peri-Surgically
A Phase 4 study of Hidradenitis Suppurativa (HS), sponsored by AbbVie.
- Completed
- Registry status
- Phase 4
- Development phase
- 206
- Enrollment target
- 20
- Study locations
NCT02808975: Completed Phase 4 study of Hidradenitis Suppurativa (HS), sponsored by AbbVie.
NCT02808975 is a Phase 4 study of Hidradenitis Suppurativa (HS) that has completed, run by AbbVie. The registered enrollment target is 206 participants, above the 163-participant average among 12 other Hidradenitis Suppurativa (HS) trials with a reported enrollment target (26% higher). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02808975, a Phase 4 study of Hidradenitis Suppurativa (HS), has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 206 participants
- Enrollment target
- 20
- Study locations
Study Summary
The objective of this study was to assess the safety and efficacy of adalimumab prior to surgery in participants with moderate to severe Hidradenitis Suppurativa (HS) who were surgical candidates.
Primary Outcome
HiSCR is defined as at least a 50% reduction in the abscess and inflammatory nodule (AN) count with no increase in abscess count and no increase in draining fistula count relative to Baseline.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Adalimumab
Study Locations (20)
Other
- Fundacion Valle Del Lili /ID# 151565 - Cali
- Hospital Pablo Tobon Uribe /ID# 152693 - Medellín
- Fakult Nem Kralovske Vinohrady /ID# 169173 - Prague
- Polyclinique Courlancy /ID# 157761 - Reims
California
- Wallace Medical Group, Inc. /ID# 171289 - Beverly Hills
- Encino Research Center / T. Jo /ID# 171347 - Encino
- University of California Irvine /ID# 170054 - Irvine
Louisiana
- Tulane Univ /ID# 168441 - New Orleans
Massachusetts
- Beth Israel Deaconess Medical Center /ID# 168438 - Boston
Michigan
- University of Michigan Hospitals /ID# 200667 - Ann Arbor
North Carolina
- Univ NC Chapel Hill /ID# 168446 - Chapel Hill
Pennsylvania
- Penn State Hershey Medical Ctr /ID# 168447 - Hershey
Rhode Island
- Rhode Island Hospital /ID# 168439 - Providence
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 206 participants |
| Start Date | 2016-07-18 |
| Est. Completion | 2019-10-16 |
| Phase | Phase 4 |
What the finished NCT02808975 record still lists
NCT02808975 is an interventional study that assigns participants to a tested intervention. The registered 206 participants enrollment target is mid-sized for trials with a published cap, above the 163-participant average among 12 other Hidradenitis Suppurativa (HS) trials with a reported enrollment target (26% higher).
The record links to 1 condition, with Hidradenitis Suppurativa (HS) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02808975 names 20 study sites across 15 states, led by Other, California, Louisiana.
Frequently Asked Questions
What is clinical trial NCT02808975 about?
NCT02808975 is a clinical study titled "Safety and Efficacy of Adalimumab (Humira) for Hidradenitis Suppurativa (HS) Peri-Surgically". The objective of this study was to assess the safety and efficacy of adalimumab prior to surgery in participants with moderate to severe Hidradenitis Suppurativa (HS) who were surgical candidates.
What is the current status of trial NCT02808975?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 206 participants. The study started on 2016-07-18. Estimated completion is 2019-10-16.
What conditions does trial NCT02808975 study?
This clinical trial studies the following conditions: Hidradenitis Suppurativa (HS).
What interventions are being tested in trial NCT02808975?
The interventions under investigation include: Placebo (DRUG), Adalimumab (DRUG).
Who is sponsoring clinical trial NCT02808975?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02808975 being conducted?
This trial has 20 study locations across California, Louisiana, Massachusetts, Michigan, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hidradenitis Suppurativa (HS)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02808975's enrollment target sits among peer trials
206 5th of 12 higher than 8 of 12 other Hidradenitis Suppurativa (HS) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hidradenitis Suppurativa (HS) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense
RECRUITING · Phase 2
-
A Study to Assess NAV-240 in Adult Participants With Hidradenitis Suppurativa
RECRUITING · Phase 2
-
The Safety and Efficacy of Roflumilast Foam in HS
RECRUITING · Phase 2
-
Participants with Mild to Moderate Hidradenitis Suppurativa Will Receive EVO101 a Topical Cream 0.1%
RECRUITING · Early Phase 1
-
1726-nm Laser for Acne Inversa (Hidradenitis Suppurativa)
RECRUITING · Phase 1
-
Pelashield™ PainGuard™ vs Restrata® in HS Surgery
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03373968 · 206 participants · Phase 2
Givinostat in Duchenne's Muscular Dystrophy Long-term Safety and Tolerability Study
- NCT03550391 · 206 participants · Phase 3
Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases
- NCT04757116 · 206 participants · NA
Post-Market Study to Assess iTind Safety in Comparison to UroLift
- NCT05675865 · 206 participants · NA
Cryoablation for Monomorphic Ventricular Tachycardia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI